PAM
MREO

Panagora Asset Management’s Mereo BioPharma MREO Stock Holding History

Panagora Asset Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,210
Closed -$20K – 2565
2019
Q2 		$20K Buy
+8,210
New +$35.9K ﹤0.01% 2284

Other funds holding MREO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Panagora Asset Management's MREO Position: Q3 2019 in Review

Panagora Asset Management sold out of Mereo BioPharma (MREO) in Q3 2019, closing a stake of 8,210 shares — an estimated $20K sold.

Panagora Asset Management first reported a position in MREO in Q2 2019 and held it in 1 quarter. The position peaked at $20K in Q2 2019. 16 funds tracked by Wall St. Rank hold MREO as of Q3 2019.

  • Panagora Asset Management reported no remaining Mereo BioPharma position as of Q3 2019 after selling out during the quarter.
  • Panagora Asset Management sold 8,210 Mereo BioPharma shares in Q3 2019, an estimated $20K.
  • Panagora Asset Management first reported a position in Mereo BioPharma in Q2 2019 and held it in 1 quarter.
  • Panagora Asset Management's Mereo BioPharma position peaked at $20K in Q2 2019.
  • 16 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.